GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2007

Molecular Partners Inks DRP Technology Agreement with Roche

  • Molecular Partners signed a collaboration agreement with Roche covering the DRP technology for a variety of undisclosed applications. Under this agreement, Molecular Partners will select DARPins to a variety of different targets, which will be provided by Roche. Roche will carry out further analyses and development. The targets and further financial terms of the agreement were not disclosed.

    DARPins constitute a novel class of binding proteins based on Molecular Partners’ designed repeat protein (DRP) technology. Due to their small size and outstanding affinity, selectivity, and stability profiles, as well as their favorable production properties in bacteria, DARPins are one of the most promising non-antibody scaffolds for in vitro and in vivo applications, according to the company.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »